Antidepressants During Pregnancy and Breastfeeding: What the Research Says

The Question Most Providers Don't Have Enough Time to Answer Well

If you're pregnant or breastfeeding and wondering whether antidepressants are safe — or whether you should start, continue, or stop them — you're asking a question that deserves more than a rushed five-minute conversation.

This article won't tell you what to do. Only your prescribing provider can do that, and the right answer depends on your specific situation: how severe your symptoms are, which medication, what dose, whether you've tried other options, and what your history looks like. What this article will do is give you accurate information about what the research actually shows, help you understand the main considerations, and suggest questions to bring to that conversation.

Why This Decision Is Hard

The core difficulty is that both sides of this equation carry real risk.

Untreated depression and anxiety during pregnancy and postpartum are not neutral. Moderate to severe perinatal depression affects fetal development, birth outcomes, breastfeeding success, and infant attachment. It also affects the parent's ability to care for themselves and their baby. The assumption that "not taking medication is the safe choice" is not supported by the evidence — it's a choice between different risk profiles, not between risk and no risk.

Medications during pregnancy and lactation do cross to the baby. Most antidepressants cross the placenta during pregnancy and pass through breast milk in varying concentrations. For the most commonly prescribed antidepressants, the evidence suggests the risk to the baby is low relative to benefit — but it is not zero, and it's not identical across all medications or all situations.

Making an informed decision means understanding both sides.

Antidepressants During Pregnancy

What the research generally shows

SSRIs (selective serotonin reuptake inhibitors) are the most studied class of antidepressants in pregnancy. Overall, the evidence base is reasonably reassuring, but it includes some risks that should be discussed with your provider:

No established link to major birth defects for most SSRIs. Early studies raised concerns, but larger, better-controlled research has not consistently found that SSRIs as a class cause major structural birth defects.

Neonatal adaptation syndrome. Babies born to mothers taking SSRIs — particularly at higher doses or later in pregnancy — may show temporary symptoms after birth: jitteriness, irritability, feeding difficulties, and mild respiratory changes. These typically resolve within the first week and don't appear to cause lasting harm.

Persistent pulmonary hypertension (PPHN). This is a rare but serious condition. Earlier studies associated SSRI use late in pregnancy with a small increase in PPHN risk. More recent research has found a much smaller association or none at all when confounders are accounted for. The absolute risk remains low.

Paroxetine (Paxil) is generally considered the SSRI with the most caution in pregnancy due to some data suggesting cardiac associations. Most guidelines recommend avoiding it if other options are effective.

SNRIs (venlafaxine, duloxetine) have a smaller evidence base than SSRIs in pregnancy but are used when SSRIs haven't been effective.

Stopping abruptly is its own risk. Discontinuing antidepressants without medical guidance can cause withdrawal symptoms and a rapid return of depression or anxiety — neither of which is safer for you or your baby than continuing medication. If you're thinking about stopping, do it with your prescriber's guidance and a tapering plan.

The question to ask your provider

"Given my specific situation — severity of symptoms, medication I'm on, where I am in my pregnancy — what are the risks of continuing versus tapering, and what does the current evidence actually support?"

Antidepressants During Breastfeeding

How exposure works

Antidepressants pass into breast milk. The question is how much — and whether that amount is clinically meaningful for the baby.

Exposure is typically measured as relative infant dose (RID): the percentage of the maternal weight-adjusted dose that the infant receives through breast milk. Medications with an RID under 10% are generally considered low-risk by most guidelines.

Which medications tend to have the best safety profile while breastfeeding

Sertraline (Zoloft) consistently appears near the top of most clinical reviews for breastfeeding safety. It has a low relative infant dose, minimal detectable levels in infant blood, and the largest evidence base of any antidepressant in lactating mothers. It is one of the most commonly prescribed antidepressants for this reason.

Paroxetine also shows low infant serum levels in breastfeeding, which is one reason it's sometimes continued during lactation even though it carries more caution in pregnancy.

Escitalopram (Lexapro) and citalopram (Celexa) are considered generally compatible with breastfeeding, though some studies show slightly higher infant exposure than sertraline.

Fluoxetine (Prozac) has a long half-life and active metabolites, which results in more measurable infant exposure than shorter-acting SSRIs. It's not contraindicated but is typically considered after others.

Nortriptyline and imipramine (older tricyclic antidepressants) have low breast milk transfer and are sometimes used when SSRIs haven't been effective, particularly for patients already stabilized on them.

LactMed — maintained by the National Institutes of Health — is a free, evidence-based database that provides regularly updated information on drugs and lactation, including specific data on relative infant dose and infant effects. Your provider can use it; you can use it too at nlm.nih.gov.

What you can ask your provider

"Can you look at the LactMed entry for this specific medication? What's the relative infant dose, and does that change your recommendation? Are there alternatives with lower transfer if my current medication is at the higher end?"

The Role of Therapy Alongside Medication

Clinical guidelines — including those from ACOG (American College of Obstetricians and Gynecologists) and APA — consistently recommend therapy as a first-line or combined treatment for perinatal depression and anxiety. For moderate to severe symptoms, the research suggests that medication and therapy together produces better outcomes than either alone.

This matters practically: if you're weighing whether to take medication, starting therapy is not "instead" — it's alongside, and it may reduce the dose of medication needed to achieve the same effect.

Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) have the strongest evidence base for perinatal depression specifically. Both are available from therapists who specialize in perinatal mental health.

If you're hesitant about medication but your symptoms are significant, therapy is a meaningful starting point — while keeping medication on the table if needed. If you're already on medication and want to eventually taper, therapy gives you the coping framework that makes tapering less likely to trigger relapse.

Having the Conversation With Your Provider

A few things to bring to the appointment:

• How severe your symptoms are (it helps to be specific — "I can't sleep even when the baby sleeps, I feel no connection to my baby, I cry most of the day" is more actionable than "I'm struggling")
• Your history with depression or anxiety before pregnancy
• Whether you've been on antidepressants before, what worked, what didn't
• Whether you're breastfeeding or plan to
• What you've already read or heard, and what concerns you most

If your provider dismisses your concerns, gives you minimal information, or makes you feel like you're overreacting — ask for a referral or seek a second opinion. Perinatal mental health treatment has a significant evidence base. You deserve a provider who engages with it seriously.

A Note on Not Starting Medication Right Now

If you and your provider decide that medication isn't the right next step — because your symptoms are mild, because you want to try therapy first, because you're early in your pregnancy and want to wait — that's a valid clinical decision.

What's not valid is deciding not to get help at all. Moderate to severe perinatal depression and anxiety do not typically resolve on their own, and the longer they go without treatment, the more they affect you, your baby, and your recovery. Whether that help is therapy, medication, or both, the starting point is the same: reach out to someone qualified.